Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

BACKGROUND: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, cou...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Prostate Int
Главные авторы: Rauch, Simon, Fong, Dominic, Morra, Elisa, Maines, Francesca, Caffo, Orazio, Spizzo, Gilbert
Формат: Artigo
Язык:Inglês
Опубликовано: Asian Pacific Prostate Society 2016
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916059/
https://ncbi.nlm.nih.gov/pubmed/27358844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.prnil.2016.02.002
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы